Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas

International Journal of Gynecological Cancer

Volumn 15, Issue 5, 2005, Pages 952-963

  Saffari, B ^a,e   Bernstein, L ^a,b   Hong, D C ^a   Sullivan Halley, J ^a   Runnebaum, I B ^c   Grill, H J ^c   Jones, L A ^d   El Naggar, A ^d   Press, Michael F ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant radiation therapy and prognosis; DNA sequence analysis; Endometrioid type endometrial carcinomas; p53

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CODON; CONTROLLED STUDY; DNA SEQUENCE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; EXON; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, ENDOMETRIOID; CODON; ENDOMETRIAL NEOPLASMS; EXONS; FEMALE; GERM CELLS; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 28944434714     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00159.x     Document Type: Article

References (58)

1. Fei P, El-Deiry W. P53 and radiation response. Oncogene 2003;22:5774-83.
2. Gudkov A, Komarova E. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117-29.
3. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis- the p53 network. J Cell Sci 2003;116:4077-85.
4. Falette N, Paperin M, Treilleux I et al. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 1998;58:1451-5.
5. Jansson T, Inganas M, Sjogren S et al. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 1995;13:2745-51.
6. Wen W, Reles A, Runnebaum I et al. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 1999;18:29-41.
7. Kressner U, Inganas M, Byding S et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999;17:593-9.
8. Koul A, Borg A, Pejovic T et al. Identification of TP53 gene mutations in uterine corpus cancer with short follow-up. Gynecol Oncol 1997;67:295-302.
9. Kihana T, Hamada K, Inoue Y et al. Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Cancer Res 1995;76:72-8.
10. Jones M, Kounelis S, Hsu C et al. Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison. Int J Gynecol Pathol 1997;16:354-60.
11. Tada M, Matsumoto R, Iggo R et al. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res 1998;58:1793-7.
12. Bergqvist M, Brattstrom D, Gullbo J, Hesselius P, Brodin O, Wagenius G. p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer. Anticancer Res 2003;23:1207-12.
13. Alsner J, Blandino G, Oren M, Shaul Y. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother. Oncol. 2001;59:179-85.
14. Gallo O, Chiarelli I, Boddi V, Boccioloni C, Bruschini L, Porfirio B. Cumulative prognostic value of p53 mutations and bc1-2 protein expression in head-and-neck cancer treated by radiotherapy. Int. J. Cancer 1999;84:573-9.
15. Yamazaki Y, Chiba I, Hirai A et al. Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma. Oral Oncol. 2003;39:163-9.
16. Storey A, Thomas M, Kalita A et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-34.
17. Marin M, Jost C, Brooks L et al. A common polymorphism acts as intragenic modifier of mutant p53 behaviour. Nat Genet 2000;25:47-54.
18. Irwin M, Kondo K, Marin M, Cheng L, Hahn W, Kaelin W Jr. Chemosensitivity linked to p73 function. Cancer Cell 2003;3:403-10.
19. Bergamaschi D, Gasco M, Hiller L et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402.
20. Dumont P, Leu J-J, Della Pietra A, George D, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
21. Buchman V, Chumakov P, Ninkina N, Samarina O, Georgiev G. A variation in the structure of the proteincoding region of the human p53 gene. Gene 1988;70:245-52.
22. Runnebaum I, Kohler T, Stickeler E, Kieback H, Kreienberg R. p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma. Br J Cancer 1996;74:1157-60.
23. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
24. Peto R, Pike M, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612.
25. Peto R, Pike M, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
26. Breslow N. Covariance analysis of censored survival data. Biometrics 1974;30:89-99.
27. Coldman A, Elwood J. Examining survival data. Can Med Assoc J 1979;121:1065-8, 1071.
28. Jemal A, Murray T, Ward E et al. Cancer Statistics, 2005. CA Cancer J Clin 2005;55:10-30.
29. Lanciano R, Greven K. Adjuvant treatment for endometrial cancer: who needs it? Gynecol Oncol 1995;57:135-7.
30. Ball H. Do we know the best therapy for early endometrial cancer? Gynecol Oncol 1996;60:173-5.
31. Kohler M, Berchuck A, Davidoff A et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
32. Ito K, Sasano H, Matsunaga G et al. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 1997;183:318-24.
33. Sjalander A, Birgander R, Hallmans G et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996;17:1313-6.
34. Kim J, Roh J, Park N, Song Y, Kang S, Lee H. Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women. Am J Obstet Gynecol 2001;184:55-8.
35. Roh J, Kim J, Park N et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 2004;93:499-505.
36. Backe J, Gassel A, Hauber K et al. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol 1997;16:361-8.
37. Geisler J, Wiemann M, Zhou Z, Miller G, Geisler H. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 1996;61:245-8.
38. Geisler J, Geisler H, Wiemann M, Zhou Z, Miller G, Crabtree W. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol 1999;74:468-71.
39. Kohler M, Carney P, Dodge R et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 1996;175:1246-52.
40. Lukes A, Kohler M, Pieper C et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-5.
41. Pisani A, Barbuto D, Chen D, Ramos L, Lagasse L, Karlan B. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995;85:729-34.
42. Reinartz J, George E, Lindgren B, Niehans G. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994;25:1075-83.
43. Soong R, Knowles S, Williams K, Hammond I, Wysocki S, Iacopetta B. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 1996;74:562-7.
44. Reles A, Wen W, Schmider A et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001;7:2984-97.
45. Sakuragi N, Salah-eldin A, Watari H et al. Bax, Bc1-2, and p53 expression in endometrial cancer. Gynecol Oncol 2002;86:288-96.
46. Buller R, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 1997;4:239-45.
47. Wang Y, Chen C, Chen S, Chang Y, Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 1999;5:129-34.
48. Sakuragi N, Hirai A, Tada M et al. Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma. Gynecol Oncol 2001;83:485-90.
49. Tashiro H, Isacson C, Levine R, Kurman R, Cho K, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:175-85.
50. Lowe S, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266: 807-10.
51. Lowe S, Ruley H, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
52. El Rouby S, Thomas A, Costin D et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82:3452-9.
53. Hsiao M, Yu A, Yeargin J, Ku D, Haas M. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood 1994;83:2922-30.
54. Vousden K. p53: death star. Cell 2000;103:691-4.
55. Martinez A, Weiner S, Podratz K et al. Improved outcome at 10 years for serous-papillary/clear cell or highrisk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation. Gynecol Oncol 2003;90:537-46.
56. Hellman S. Stopping metastases at their source. N Engl J Med 1997;337:996-7.
57. Overgaard M, Hansen P, Overgaard J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-55.
58. Komarova E, Christov K, Faerman A, Gudkov A. Different impact of p53 and p21 on the radiation response of mouse tissues. Oncogene 2000;19:3791-8.